GeoVax files for $5 million offering as Xbrane's ranibizumab approval stands

GeoVax Labs, Inc. filed a Form S-1 with the SEC on November 3, 2026 for a firm commitment underwritten public offering of 29,585,798 shares of common stock, plus pre-funded warrants for the same number of shares. The assumed public offering price is $0.169 per share, based on the last reported Nasdaq sale price on October 30, 2026.¹ E.F. Hutton & Co. is acting as sole book-running manager and sole underwriter, with a firm commitment to purchase all shares and pre-funded warrants offered.¹

GeoVax estimates net proceeds of approximately $4,628,000 from the offering, after deducting the underwriting discount, the non-accountable expense allowance and estimated offering expenses.¹ The company plans to use proceeds to advance its product candidates, including the planned Phase 3 clinical trial of GEO-MVA, along with research, manufacturing, clinical studies, and general corporate purposes, including up to $2.5 million for marketing and advertising services aimed at the financial community.¹

GeoVax's near-term priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses, advancing under an expedited regulatory pathway with plans to start a pivotal Phase 3 trial in the fourth quarter of 2026.¹ Its lead oncology program, Gedeptin, a gene-directed therapy for head and neck cancers, recently completed a Phase 1/2 trial, with a Phase 2 combination study with an immune checkpoint inhibitor planned for the second half of 2027.¹

The filing discloses new financing and governance developments. On October 25, 2026, GeoVax entered a Revolving Loan Agreement with Bowery Consulting Group Inc. allowing borrowing up to $1,000,000 at any time.¹ Two days earlier, on October 23, 2026, five directors resigned and the remaining board appointed three individuals designated by the lender, Steven Brown, Tyler O'Brien and Manpreet Uppal, as directors.¹

GeoVax also disclosed that Nasdaq had determined to delist its common stock after its closing bid price stayed below $1.00 for 30 consecutive business days, with a hearing before the Nasdaq Hearings Panel held October 13, 2026.¹

Separately, the FDA's drugs@FDA database continues to list ranibizumab, filed under BLA761187 by sponsor Xbrane Biopharma AB, with approval status dated October 27, 2026, and accompanying approval letter and label documents dated October 30, 2026, as previously reported.